Ioniparin

Ioniparin is a low molecular weight heparin (LMWH) that acts as an anticoagulant. It is derived from unfractionated heparin through a process of controlled depolymerization. The primary mechanism of action for ioniparin, like other LMWHs, involves potentiating the activity of antithrombin III. This complex then inactivates coagulation factors Xa and IIa (thrombin), thereby inhibiting the coagulation cascade and preventing thrombus formation. Ioniparin is administered via subcutaneous injection. It is used for the prophylaxis and treatment of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. It may also be used in certain situations for patients with unstable angina or non-ST-elevation myocardial infarction. The pharmacokinetic profile of ioniparin is characterized by a longer half-life and more predictable anticoagulant response compared to unfractionated heparin, allowing for less frequent dosing and the potential for outpatient management. Monitoring of anticoagulant effect is generally not required for ioniparin when used at standard doses, although anti-Xa levels may be considered in specific patient populations such as those with severe renal impairment or obesity. Potential side effects include bleeding, which is the most common and significant adverse event, and thrombocytopenia. Contraindications include active bleeding, hypersensitivity to the drug, and severe uncontrolled hypertension.